Clinical parameters affecting multipotent adult progenitor cells in vitro

Area of Science:

• Regenerative Medicine
• Neuroscience
• Cell Therapy

Background:

• Multipotent adult progenitor cells (MAPC®) show promise for treating traumatic brain injury (TBI).
• Clinical translation requires understanding in vitro factors impacting cell therapy efficacy.

Purpose of the Study:

• To assess the impact of clinical parameters on MAPC viability and function.
• To evaluate the effects of needle gauge, co-culture with drugs, and osmolarity on MAPC.

Main Methods:

• MAPC viability was tested after infusion through needles/catheters and exposure to chlorhexidine.
• MAPC were co-cultured with phenytoin and celecoxib, and their anti-inflammatory potency was assessed.
• MAPC were cultured under varying osmolar concentrations and their proliferation was measured.

Main Results:

• MAPC viability remained high (>90%) after needle infusion, but was reduced by chlorhexidine.
• Phenytoin and celecoxib did not impair MAPC function; phenytoin decreased TNF-α production.
• Osmolarity variations did not affect MAPC viability, but co-culture with activated PBMCs reduced MAPC proliferation.

Conclusions:

• Needle diameter, phenytoin, celecoxib, and physiological osmolarities do not compromise MAPC viability or anti-inflammatory properties in vitro.
• Chlorhexidine negatively impacts MAPC viability.
• MAPC retain therapeutic potential despite exposure to certain clinical handling conditions.